BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 19690035)

  • 1. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
    Hawkins DS; Schuetze SM; Butrynski JE; Rajendran JG; Vernon CB; Conrad EU; Eary JF
    J Clin Oncol; 2005 Dec; 23(34):8828-34. PubMed ID: 16314643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
    Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
    Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model.
    Song SL; Deng C; Wen LF; Liu JJ; Wang H; Feng D; Wong CY; Huang G
    Nucl Med Biol; 2010 Apr; 37(3):327-33. PubMed ID: 20346872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of children with partial epilepsy: MRI and serial 18FDG-PET.
    Gaillard WD; Weinstein S; Conry J; Pearl PL; Fazilat S; Fazilat S; Vezina LG; Reeves-Tyer P; Theodore WH
    Neurology; 2007 Feb; 68(9):655-9. PubMed ID: 17325271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
    Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase (18)F-FDG PET/CT.
    Byun BH; Kim SH; Lim SM; Lim I; Kong CB; Song WS; Cho WH; Jeon DG; Lee SY; Koh JS; Chung SK
    Eur Radiol; 2015 Jul; 25(7):2015-24. PubMed ID: 25680716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
    Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
    Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
    J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential ¹⁸F-FDG PET/CT and MRI.
    Byun BH; Kong CB; Lim I; Kim BI; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1553-62. PubMed ID: 24652233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
    Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1)H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography.
    Tozaki M; Sakamoto M; Oyama Y; O'uchi T; Kawano N; Suzuki T; Yamashiro N; Ozaki S; Sakamoto N; Higa K; Abe S; Ogawa T; Fukuma E
    J Magn Reson Imaging; 2008 Aug; 28(2):420-7. PubMed ID: 18666159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation.
    Wykrzykowska J; Lehman S; Williams G; Parker JA; Palmer MR; Varkey S; Kolodny G; Laham R
    J Nucl Med; 2009 Apr; 50(4):563-8. PubMed ID: 19289431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.